WebMar 16, 2024 · Based in Seattle, WA, CTI BioPharma is a small health care company with only 46 employees and an annual revenue of $3.3M. The Organization’s Mission. We are on a mission to make a meaningful impact on the lives of patients with blood-related cancers.-Employee Reviews. WebNov 7, 2024 · About CTI BioPharma Corp. We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers.
CTI Biopharma Corp. Company Profile Seattle, WA Competitors ...
WebDec 13, 2024 · SEATTLE, Dec. 13, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) announced five scientific poster presentations on the pacritinib clinical program at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held as a hybrid (virtual and live) meeting in Atlanta, Georgia, December 11-14, 2024. "We are … WebApr 10, 2024 · SEATTLE, April 10, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for ... reach radar
CTI BioPharma Announces Inducement Grants Under Nasdaq …
WebVice President and Head of Clinical Affairs. CTI BioPharma. Oct 2024 - Present4 months. Seattle, Washington, United States. WebMar 6, 2024 · CTI develops novel therapies for patients with rare blood-related cancers by uncovering the underlying scientific drivers of their disease. Learn More Approved in the … Myelofibrosis is a rare, heterogeneous, debilitating, progressive bone marrow … CTI Access; Medicine Support; Development. Development Overview; … CTI provides comprehensive medical, dental and vision coverage with low … Pacritinib for Other Indications. Graft Versus Host Disease. The combination of … Careers - CTI BioPharma Targeted Blood Cancer Therapies Home Adam R. Craig, M.D., Ph.D., M.B.A. is President. Chief Executive Officer and … The PRE-VENT study was a randomized, double-blind, placebo-controlled … At CTI, we are all deeply connected to each other and our work, united in our quest … Publications & Posters - CTI BioPharma Targeted Blood Cancer Therapies Home WebThe all-time high CTI BioPharma stock closing price was 878520.00 on October 20, 2000. The CTI BioPharma 52-week high stock price is 7.80, which is 75.7% above the current share price. The CTI BioPharma 52-week low stock price is 3.32, which is 25.2% below the current share price. The average CTI BioPharma stock price for the last 52 weeks is 5.51. reach radiator 2917